GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Octreotide - SANDOSTATIN LAR DEPOT injection

Local RX List renal extractBase record retrieved 2026-09-09See the evidence for this drug1 sources available - open source summaries, references and comparisons

SANDOSTATIN LAR DEPOT / Octreotide

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
SANDOSTATIN LAR: dialysis starting dose is not a permanent ceiling

The depot renal instruction concerns initiation. Maintenance and short-acting overlap remain indication-specific.

Before applying: Confirm depot formulation, prior short-acting treatment and the indication-specific transition. Do not apply the depot starting dose to oral octreotide.

Also check: SANDOSTATIN LAR: dialysis starting dose is not a permanent ceiling

Rxlist source

GlobalRPh RX List - SANDOSTATIN LAR DEPOT

Product / population
Octreotide - SANDOSTATIN LAR DEPOT injection; selected source sections only, not a complete prescribing monograph.
Renal measure
Qualitative renal statement; no numerical renal algorithm inferred.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

For renal failure requiring dialysis, start the long-acting intragluteal injection at 10 mg every 4 weeks. Other renal impairment uses the nonrenal starting dose, 20 mg every 4 weeks. Adjust maintenance to response and tolerability. These are starting instructions, not universal maintenance ceilings. Preserve the indication-specific transition: carcinoid/VIPoma patients switching from subcutaneous Sandostatin continue the prior subcutaneous dose for at least 2 weeks; some need 3-4 weeks. Do not apply this depot schedule to oral or short-acting octreotide.

Source revision: RX page prints July 2024. | Retrieved: 2026-09-09. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/sandostatin-lar-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - SANDOSTATIN LAR DEPOT

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Octreotide - SANDOSTATIN LAR DEPOT injection; selected source sections only, not a complete prescribing monograph.

Renal method: Qualitative renal statement; no numerical renal algorithm inferred.
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

SANDOSTATIN LAR: dialysis starting dose is not a permanent ceiling

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

dialysis scope

SANDOSTATIN LAR: dialysis starting dose is not a permanent ceiling

The depot renal instruction concerns initiation. Maintenance and short-acting overlap remain indication-specific.

How to use this: Confirm depot formulation, prior short-acting treatment and the indication-specific transition. Do not apply the depot starting dose to oral octreotide.

GlobalRPh RX List - SANDOSTATIN LAR DEPOTOctreotide - MYCAPSSA oral capsules

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - SANDOSTATIN LAR DEPOT
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/sandostatin-lar-drug/

Exact product and population

Octreotide - SANDOSTATIN LAR DEPOT injection; selected source sections only, not a complete prescribing monograph.

RDM49-SCOPE-octreotide-sandostatin-lar · Source section: Selected source product scopeRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - SANDOSTATIN LAR DEPOT

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Octreotide - SANDOSTATIN LAR DEPOT injection; selected source sections only, not a complete prescribing monograph.

Renal method: Qualitative renal statement; no numerical renal algorithm inferred.
Source date: RX page prints July 2024.
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For renal failure requiring dialysis, start the long-acting intragluteal injection at 10 mg every 4 weeks. Other renal impairment uses the nonrenal starting dose, 20 mg every 4 weeks. Adjust maintenance to response and tolerability. These are starting instructions, not universal maintenance ceilings. Preserve the indication-specific transition: carcinoid/VIPoma patients switching from subcutaneous Sandostatin continue the prior subcutaneous dose for at least 2 weeks; some need 3-4 weeks. Do not apply this depot schedule to oral or short-acting octreotide.

RDM49-rxlist-octreotide-sandostatin-lar-d2f1d6cded-C1 · Source locator: Dosage: special populations, lines 91-95; transition instructions, lines 80-90; renal population subsection.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/sandostatin-lar-drug/
Retrieved
2026-09-09
Renal-function method
Qualitative renal statement; no numerical renal algorithm inferred.
Source date/version
RX page prints July 2024.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
4524dfbe7b31b10cc6e3a786b23d21f804015bbdcc144bdf0839a2e249e97770

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/sandostatin-lar-drug/
Source retrieval
2026-09-09. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
c739ab1d7cfd451b635e61c6e5bd0636c5c621e18a9eb497bc404fffc070eab1
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report